ALPHARMA INC
AMENDMENT NO. 1 TO THE CREDIT AGREEMENT
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>revisedamendment_no1.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE CREDIT AGREEMENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Form</TITLE>
<META NAME="DocID" CONTENT="NYDOCS03/658069.5">
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">

<FONT SIZE=3><P ALIGN="RIGHT"></P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<B><P ALIGN="CENTER">AMENDMENT NO. 1 TO THE</P>
<P ALIGN="CENTER">CREDIT AGREEMENT <SUP>1</P>
</SUP><P ALIGN="CENTER"></P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

</B><P>Dated as of December 16, 2002</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<B><P>AMENDMENT NO. 1 TO THE CREDIT AGREEMENT </B>among ALPHARMA INC., a Delaware corporation ("<B><I>Holdings</B></I>"), the banks, financial institutions and other lenders party hereto, and BANK OF AMERICA, as administrative agent and collateral agent (the "<B><I>Administrative Agent</B></I>"), as parties to the Credit Agreement  referred to below.</P>
<B><P>PRELIMINARY STATEMENTS:</P>
<OL>
<DIR>
<DIR>

<OL>

</B><LI>Alpharma Operating Corporation, a Delaware corporation (the "<B><I>Company</B></I>"), Alpharma USPD Inc., a Maryland corporation (together with the Company and the Subsidiary Borrowers party thereto, the "<B><I>Borrowers</B></I>"), Holdings, the Lender Parties and the Administrative Agent have entered into a Credit Agreement dated as of October&nbsp;5, 2001 (as amended, supplemented or otherwise modified from time to time, the "<B><I>Credit Agreement</B></I>").  Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement.</LI>
<LI>Holdings and the Required Lenders have agreed to amend the Credit Agreement as hereinafter set forth.</LI>
<OL>

<U><LI>Amendments to Credit Agreement</LI>
</U><P>.  The Credit Agreement is, effective as of the date hereof and subject to the satisfaction of the conditions precedent set forth in Section&nbsp;3, hereby amended as follows:</P>
<P>(a)&#9;Article I is amended by adding the following new terms in alphabetical order:</P>
<P>"<U>Amendment No. 1 Effective Date</U>" means the date on which Amendment No.&nbsp;1 to the Credit Agreement, dated as of December&nbsp;16, 2002, among Holdings, the Administrative Agent and the Required Lenders, becomes effective pursuant to Section 3 thereof.</P>
<P>"<U>Specified Restructurings</U>" means the (i) closing of the Alpharma Animal Health Company facilities located in Hannibal, Missouri, Lowell, Arkansas, Parkville, Australia and Wrightstown, New Jersey and related employee headcount reductions and (ii) employee headcount reductions of approximately 160 positions, with notifications thereof expected to occur by the end of March 31, 2003. </P>
<B><P>______________________</P>
<P>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INDICATES THAT MATERIAL HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P>
</B>
<P>&nbsp;</P>
<P>"<U>Specified Sales</U>" means the sale, licensing, transfer or other disposition of one or more of the following from time to time: (i) all or any portion of the Equity Interests, properties and assets related to the manufacture and sale of the "Norgeplaster" adhesive bandage business, (ii) all or any portion of the Equity Interests, properties and assets related to the manufacture and sale of the Norwegian vitamin business, (iii) all or any portion of rights or interests related to the ********* business, (iv) all or any portion of rights or interests related to the ******* business and (v) all or any portion of any land and facilities or other assets in connection with the Specified Restructurings.</P>
<P>(b)&#9;The definition of "Consolidated EBITDA" in Article&nbsp;I is amended by (i) inserting after clause (j) therein the following new clause to read as follows:</P>
<P>"<I>plus</I> (k) all cash expenses and charges up to a maximum aggregate amount of $25,000,000 of Holdings or any of its Subsidiaries incurred in connection with the Specified Restructurings",</P>
<P>and (ii) relabeling existing clause (k) as new clause (l).</P>
<P>(c)&#9;The definition of "Debt Securities" in Article&nbsp;I is amended by inserting at the end thereof the following new clause to read as follows:</P>
<P>"; <I>provided</I> that convertible subordinated notes of the Company, with (i) a cash interest rate not in excess of 12% per annum, (ii) a maturity date occurring no sooner than December 15, 2009, (iii) financial and other operating covenants less restrictive by a factor of 10% than those contained in this Agreement and (iv) no additional or more restrictive defaults, required prepayment, required redemption or other similar terms more restrictive on, or less favorable to, the Company than those contained in this Agreement, shall be considered "Debt Securities" for all purposes of this Agreement".</P>
<P>(d)&#9;The definition of "Fixed Charge Coverage Ratio" in Article&nbsp;I is amended by deleting the phrase "for the most recently completed Measurement Period" in clause (v) thereof and substituting therefor the phrase "during the most recently completed Measurement Period".</P>
<P>(e)&#9;Section 2.06(b)(ii) is amended by inserting at the end of the second sentence thereof a new clause to read as follows:</P>
<P>"; <I>provided</I> that 100% of the Net Cash Proceeds from the Specified Sales shall, to the extent such Specified Sales are permitted by, and only by, Section 5.02(e)(v), be applied by the Company, subject to Section 2.06(b)(viii), within ten (10) Business Days of receipt by Holdings or any of its Subsidiaries from time to time to prepay an aggregate principal amount of the Advances equal to 100% of such Net Cash Proceeds so received (it being understood that such sales shall, in addition to the other requirements for such sales specified in Section 5.02(e)(v),  in each case be consummated on commercially reasonable terms as determined by the Company)." </P>
<P>(f)&#9;Section&nbsp;2.11(d) is amended by deleting the words "Eurodollar Rate" which appear in the proviso thereof. </P>
<P>(g)&#9;Section&nbsp;5.02(e)(v) is amended by inserting at the end thereof a new clause to read as follows:</P>
<P>"; <I>provided</I> that the Specified Sales may be made without giving effect to the $5,000,000 or $10,000,000 limitations specified in this clause (v) and such limitations shall be calculated excluding the Specified Sales".</P>
<P>(h)&#9;Section&nbsp;5.02(j) is amended by inserting after clause (vi) the following new clauses "(vii) and (viii)" to read as follows: </P>
<P>"(vii) prepayment of the three local currency loans provided to Alpharma AS by Union Bank of Norway, Nordic Investment Bank and Statens n&aelig;rings-og distriksutviklingsfond, in the aggregate principal amount of approximately $7,702,000, through the use of a borrowing by Alpharma AS under its existing $30,000,000 multicurrency credit facility (it being understood that in connection with such prepayments, the Company will concurrently optionally prepay $7,500,000 of Term Advances pursuant to Section 2.06(a)) and (viii) prepayment of the industrial revenue bonds issued with respect to properties located in Baltimore, Maryland and Lincolnton, North Carolina (it being understood that the Company will otherwise comply with the requirements specified in Section 5.01(r)(D) in connection with the prepayment of such industrial revenue bonds)".</P>
<P>(i)&#9;Section&nbsp;5.03 is amended by adding to the end thereof the following new clause "(r)" to read as follows:</P>
<P>"(r) &#9;<U>Certain FDA Reports</U>.  &#9;(i) Promptly after the same becomes available to the Company, with respect to each manufacturing facility of Holdings or its Subsidiaries located in the United States: (A) all warning letters alleging violations of FDA regulatory requirements at such manufacturing facility and (B)&nbsp;all inspectional observations recorded on a Form FD 483 and issued by the FDA at the conclusion of any FDA inspections of such facility (other than pre-approval inspections and post-approval inspections) that would be required to be publicly disclosed by the Company in a filing with the Securities and Exchange Commission and (ii) promptly after the sending or filing thereof, all written responses to the FDA by or on behalf of Holdings or its Subsidiaries concerning alleged violations of FDA regulatory requirements contained in warning letters or Form FD 483s referred to in the foregoing clause (i) of this Section 5.03(r)."</P>
<P>(j)&#9;Section&nbsp;5.04(e) is amended by adding to the end thereof the following new clause to read as follows:</P>
<P>"<U>less</U> (iv) an amount equal to the lesser of (A) $75,000,000 and (B) the amount of all Consolidated cash and non-cash charges of Holdings and its Subsidiaries taken for the Fiscal Quarter ended December 31, 2002." </P>
<U><LI>Fees</LI>
</U><P>.  On the date hereof, Holdings shall pay to the Administrative Agent, for the benefit of each Lender that executes this Amendment <B><U>by no later than 5:00 PM (New York time) on Monday, December 16, 2002</B></U>, an upfront fee equal to 0.05%<B> </B>of the aggregate Commitments of each such Lender under the Credit Agreement as of the date hereof (without giving effect to the Commitment reduction specified in Section 4 hereof).</P>
<U><LI>Conditions of Effectiveness</LI>
</U><P>.  This Amendment shall become effective as of the date first above written when, and only when, the Administrative Agent shall have received counterparts of this Amendment executed by Holdings and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Administrative Agent that such Lender has executed this Amendment; and Section 1 of this Amendment shall become effective when and only when the Administrative Agent shall have received (a) the fees specified in Section 2 hereof, and payment of all other accrued fees and expenses of the Administrative Agent (including the reasonable accrued fees and expenses of counsel to the Administrative Agent invoiced on or prior to the date hereof) and (b) all of the following documents, each such document dated the date of receipt thereof by the Administrative Agent (unless otherwise specified), in form and substance satisfactory to the Administrative Agent:</P><OL TYPE="a">

<OL TYPE="i">

<LI>Counterparts of the Consent appended hereto (the "<B><I>Consent</B></I>"), executed by each of the Loan Parties (other than Holdings); </LI>
<LI>Certified copies of (A)&nbsp;the resolutions of the Board of Directors of (1)&nbsp;Holdings approving this Amendment and the matters contemplated hereby and (2)&nbsp;each other Loan Party evidencing approval of the Consent and (B)&nbsp;all documents evidencing other necessary corporate action and governmental approvals, if any, with respect to this Amendment, the Consent and all other matters contemplated hereby;</LI>
<LI>A certificate signed by a duly authorized officer of Holdings stating that: (A) the representations and warranties contained in Section&nbsp;5 hereof and in the Loan Documents are true and correct on and as of the date of such certificate as though made on and as of such date other than any such representations or warranties that, by their terms, refer to a date other than the date of such certificate, and (B) no event has occurred and is continuing that constitutes a Default.</LI></OL>
</OL>

<U><LI>Revolving Credit Commitment Reduction</LI>
</U><P>.  On the Amendment No. 1 Effective Date, the Revolving Credit Commitments shall be automatically and permanently reduced, on a Pro Rata basis, by $150,000,000 in the aggregate.</P>
<U><LI>Representations and Warranties of Holdings</LI>
</U><P>.  Holdings hereby represents and warrants as follows:</P>
<OL TYPE="a">

<LI>Each Loan Party is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation.</LI>
<LI>The execution, delivery and performance by each Loan Party of this Amendment and the Consent, as applicable, to which it is a party, are within such Person's corporate or other powers, have been duly authorized by all necessary corporate or other action and do not (i)&nbsp;contravene such Person's Constitutive Documents, (ii)&nbsp;violate any Requirement of Law, (iii)&nbsp;conflict with or result in the breach of, or constitute a default under, any contract, loan agreement, indenture, mortgage, deed of trust, lease or other instrument binding on or affecting any Loan Party, any of its Subsidiaries or any of their properties or (iv)&nbsp;except for the Liens created under the Collateral Documents,  result in or require the creation or imposition of any Lien upon or with respect to any of the properties of any Loan Party or any of its Subsidiaries.</LI>
<LI>No Governmental Authorization, and no other authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required for the due execution, delivery or performance by any Loan Party of this Amendment or the Consent.</LI>
<LI>This Amendment and the Consent have been duly executed and delivered by each Loan Party which is a party thereto.  This Amendment and the Consent are legal, valid and binding obligations of each Loan Party which is a party thereto, enforceable against each such Loan Party in accordance with their respective terms.</LI>
<LI>There is no action, suit, investigation, litigation or proceeding affecting any Loan Party or any of its Subsidiaries pending or, to the knowledge any Loan Party, threatened before any Governmental Authority or arbitrator that&nbsp;purports to affect the legality, validity or enforceability of this Amendment or the Consent, or the consummation of any of the transactions contemplated hereby.</LI>
<LI>The execution, delivery and performance of this Amendment and the Consent do not adversely affect the Liens created under any of the Collateral Documents.</LI></OL>

<U><LI>Reference to and Effect on the Loan Documents</LI>
</U><P>.  (a)  On and after the effectiveness of this Amendment, each reference in the Credit Agreement to "this Agreement", "hereunder", "hereof" or words of like import referring to the Credit Agreement, and each reference in the Notes and each of the other Loan Documents to "the Credit Agreement", "thereunder", "thereof" or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement, as amended by this Amendment.</P><OL TYPE="a">
<OL TYPE="i">

<OL START=2 TYPE="a">

<LI>The Credit Agreement, the Notes and each of the other Loan Documents, as specifically amended by this Amendment,  are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.  Without limiting the generality of the foregoing, the Collateral Documents and all of the Collateral described therein do and shall continue to secure the payment of all Obligations of the Loan Parties under the Loan Documents, in each case as amended by this Amendment.</LI>
<LI>The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under any of the Loan Documents, nor constitute a waiver of any provision of any of the Loan Documents.</LI></OL>
</OL>
</OL>

<U><LI>Costs, Expenses</LI>
</U><P>.  The Borrower agrees to pay on demand all costs and expenses of the Administrative Agent in connection with the preparation, execution, delivery and administration, modification and amendment of this Amendment and the other instruments and documents to be delivered hereunder (including, without limitation, the reasonable fees and expenses of counsel for the Administrative Agent) in accordance with the terms of Section&nbsp;8.04 of the Credit Agreement.  </P>
<U><LI>Execution in Counterparts</LI>
</U><P>.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.  Delivery of an executed counterpart of a signature page to this Amendment by telecopier shall be effective as delivery of a manually executed counterpart of this Amendment.  </P>
<U><LI>Governing Law</LI></OL>
</OL>
</DIR>
</DIR>
</OL>

</U><P>.  This Amendment shall be governed by, and construed in accordance with, the laws of the State of New&nbsp;York.</P>

<P ALIGN="CENTER">[remainder of this page intentionally left blank]</P>
<P ALIGN="CENTER"></P>
<P>IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized, as of the date first above written.</P>

<P>&nbsp;</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>ALPHARMA INC.</P>
<P>By:<U>/s/ Matthew Farrell&#9;</U><BR>
Title:  Executive Vice President, Finance<BR>
&#9;and Chief Financial Officer</P>

<P>&nbsp;</P>
<P>BANK OF AMERICA, N.A., </P>
<P>  as Administrative Agent and Lender</P>
<P>By:<U>/s/ Joseph L. Corah&#9;</U><BR>
Title:  Principal</P>

<P>&#9;</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P>Agreed as of the date first above written:</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=736>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>BNP PARIBAS<BR>
By:<U>/s/ Shayn March<BR>
</U>Title: Vice President<BR>
</P>
<P>By:<U>/s/ Stephanie Rogers<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>BNP PARIBAS, OSLO BRANCH<BR>
By:<U>/s/ Cecilia Stenkula<BR>
</U>Title:  General Manager<BR>
</P>
<P>By:<U>/s/ Mikkel A. Vogt<BR>
</U>Title:  General Manager - Corporate</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>CIBC, INC.<BR>
By:<U>/s/ Lindsay Gordon<BR>
</U>Title:  Executive Director</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>CITICORP USA, INC.<BR>
By:<U>/s/ Allen Fisher|</P>
</U><P>Title:  Vice President</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>DEN NORSKE BANK<BR>
By:<U>/s/ Philip F. Kurpiewski<BR>
</U>Title:  First Vice President</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>FLEET NATIONAL BANK<BR>
By:<U>/s/ Roger Boucher<BR>
</U>Title:  </P>
</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>IKB CAPITAL CORPORATION<BR>
By:<U>/s/ David Snyder<BR>
</U>Title:  President</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>LANDESBANK SCHLESWIG-HOLSTEIN GIROZENTRALE, COPENHAGEN BRANCH<BR>
By:<U>/s/ Finn Bergman<BR>
</U>Title:<BR>
By:<U>/s/ Steffen Andersen<BR>
</U>Title:</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>NATIONAL CITY BANK<BR>
By:<U>/s/ Kevin M. Knopf<BR>
</U>Title:  Assistant Vice President</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>UNION BANK OF NORWAY<BR>
By:<U>/s/ Terje Straume<BR>
</U>Title:  General Manager</FONT></TD>
</TR>
</TABLE>


<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=736>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ADDISON CDO, LIMITED (#1279)<BR>
By:<U>/s/ Mohan V. Phansalkar<BR>
</U>Title:  Executive Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>AERIES FINANCE-II LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>AIM FLOATING RATE FUND<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ALLIANCE CAPITAL FUNDING, L.L.C.<BR>
By:<U>/s/ Teresa McCarthy<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ALLSTATE LIFE INSURANCE COMPANY<BR>
By:<U>/s/ Chris Goergen<BR>
</U>Title:  Authorized Signatory<BR>
By:<U>/s/ Jerry D. Zinkula<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>AMARA 2 FINANCE, LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>AMERICAN EXPRESS CERTIFICATE COMPANY<BR>
By:<U>/s/ Steven B. Staver<BR>
</U>Title:  Managing Director</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>AMMC CDO II, LIMITED<BR>
By:<U>/s/ David P. Meyer<BR>
</U>Title:  Vice President</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ANTARES CAPITAL CORPORATION<BR>
By:<U>/s/ David Mahon<BR>
</U>Title:  Director</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ANTARES FUNDING TRUST<BR>
By:<U>/s/ Leslie Hundley<BR>
</U>Title:  Officer</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>APEX (Trimaran) CDO I, LTD.<BR>
By:<U>/s/ David M. Millison<BR>
</U>Title:  Managing Director</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ARCHIMEDES FUNDING III, LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ARCHIMEDES FUNDING IV (CAYMAN), LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ATHENA CDO, LIMITED (#1277)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>AVALON CAPITAL LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>AVALON CAPITAL LTD. 2<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>BLACK DIAMOND CLO 1998-1 LTD.<BR>
By:<U>/s/ Alan Corkish<BR>
</U>Title:  Director</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>BLACK DIAMOND CLO 2000-1 LTD.<BR>
By:<U>/s/ Alan Corkish<BR>
</U>Title:  Director</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>BRYN MAWR CLO, LTD.<BR>
By:<U>/s/ Dale Burrow<BR>
</U>Title:  Senior Vice President</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>CALIFORNIA PUBLIC EMPLOYEES' RETIREMENT SYSTEM (#2980)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CAPTIVA III FINANCE LTD. (ACCT. 275)<BR>
By:<U>/s/ David Dyer<BR>
</U>Title:  Director</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>CAPTIVA IV FINANCE LTD. (ACCT. 1275)<BR>
By:<U>/s/ David Dyer<BR>
</U>Title:  Director</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CATALINA CDO LTD. (#1287)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>CENTURION CDO II, LTD.<BR>
By:<U>/s/ Steven B. Staver<BR>
</U>Title:  Managing Director</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CENTURION CDO VI, LTD.<BR>
By:<U>/s/ Steven B. Staver<BR>
</U>Title:  Managing Director</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>CERES II FINANCE LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CHARTER VIEW PORTFOLIO<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>CITIGROUP INVESTMENTS CORPORATE LOAN FUND INC.<BR>
By:<U>/s/ Matthew J. McInerny<BR>
</U>Title:  Investment Officer</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CLYDESDALE CLO 2001-1, LTD.<BR>
By:<U>/s/ Elizabeth MacLean<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>COLUMBUS LOAN FUNDING, LTD.<BR>
By:<U>/s/ Matthew J. McInerny<BR>
</U>Title:  Investment Officer</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>CONTINENTAL CASUALTY COMPANY<BR>
By:<U>/s/ Marilou R. McGirr<BR>
</U>Title:  Vice President</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>DELANO COMPANY (#274)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>DIVERSIFIED CREDIT PORTFOLIO LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ENDURANCE CLO I, LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>FIDELITY ADVISOR SERIES II<BR>
By:<U>/s/ Francis V. Knox, Jr.<BR>
</U>Title:</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>FRANKLIN CLO I, LIMITED<BR>
By:<U>/s/ Richard D'Addario<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>FRANKLIN CLO II, LIMITED<BR>
By:<U>/s/ Richard D'Addario<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>FRANKLIN FLOATING RATE DAILY ACCESS FUND<BR>
By:<U>/s/ Richard D'Addario<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>FRANKLIN FLOATING RATE MASTER SERIES<BR>
By:<U>/s/ Richard D'Addario<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>FRANKLIN FLOATING RATE TRUST<BR>
By:<U>/s/ Richard D'Addario<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>GALAXY CLO 1999-1, LTD.<BR>
By:<U>/s/ Steven S. Oh<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>HARBOURVIEW CDO II, LTD, FUND<BR>
By:<U>/s/ Bill Campbell<BR>
</U>Title:  Manager</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>HARBOURVIEW CLO IV, LTD, FUND<BR>
By:<U>/s/ Bill Campbell<BR>
</U>Title:  Manager</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>IDS LIFE INSURANCE COMPANY<BR>
By:<U>/s/ Steven B. Staver<BR>
</U>Title:  Managing Director</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ING INVESTMENTS, LLC<BR>
By:<U>/s/ Michel Prince<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ING PRIME RATE TRUST<BR>
By:<U>/s/ Michel Prince<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ING SENIOR INCOME FUND<BR>
By:<U>/s/ Michel Prince<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>INVESCO CBO 2000-1 LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>J.H. WHITNEY MARKET VALUE FUND, L.P.<BR>
By:<U>/s/ Marc S. Diagonale<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>JISSEKIKUN FUNDING, LTD. (#1288)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>KATONAH I, LTD.<BR>
By:<U>/s/ Ralph Della Rocca<BR>
</U>Title:  Authorized Officer</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>KATONAH II, LTD.<BR>
By:<U>/s/ Ralph Della Rocca<BR>
</U>Title:  Authorized Officer</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>KATONAH III, LTD.<BR>
By:<U>/s/ Ralph Della Rocca<BR>
</U>Title:  Authorized Officer</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>KZH CNC LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>KZH CYPRESSTREE-1 LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>KZH ING-2 LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>KZH RIVERSIDE LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>KZH SOLIEL LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>KZH SOLIEL-2 LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>KZH STERLING LLC<BR>
By:<U>/s/ Anthony Iarrobino<BR>
</U>Title:  Authorized Agent</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>LONG LANE MASTER TRUST IV<BR>
By:<U>/s/ Darcey Bartel<BR>
</U>Title:  Director</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>MAGMA CDO LTD.<BR>
By:<U>/s/ Kaitlin Trinh<BR>
</U>Title:  Fund Controller</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ML CLO XII PILGRIM AMERICA (CAYMAN) LTD.<BR>
By:<U>/s/ Michel Prince<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>MONUMENT CAPITAL LTD.<BR>
By:<U>/s/ Teresa McCarthy<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>MORGAN STANLEY PRIME INCOME TRUST<BR>
By:<U>/s/ Peter Gewirtz<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>NEMEAN CLO, LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>NEW ALLIANCE GLOBAL CDO, LIMITED<BR>
By:<U>/s/ Teresa McCarthy<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>NOMURA BOND AND LOAN FUND<BR>
By:<U>/s/ Elizabeth MacLean<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>OPPENHEIMER SENIOR FLOATING RATE FUND<BR>
By:<U>/s/ Bill Campbell<BR>
</U>Title:  Manager</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ORIX FINANCE CORP. I<BR>
By:<U>/s/ Sheppard H.C. Davis, Jr.<BR>
</U>Title:  Authorized Representative</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ORYX CLO, LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>PILGRIM CLO 199-1 LTD.<BR>
By:<U>/s/ Michel Prince<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>PROTECTIVE LIFE INSURANCE COMPANY<BR>
By:<U>/s/ Diane S. Griswold<BR>
</U>Title:  AVP</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>PRUDENTIAL SERIES FUND INCORPORATED (#1241)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>PVIT HIGH YIELD BOND PORTFOLIO (#686)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>ROSEMONT CLO, LTD.<BR>
By:<U>/s/ Dale Burrow<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>ROYALTON COMPANY (#280)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>SAN JOAQUIN CDO I LIMITED (#1282)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>SEABOARD CLO 2000 LTD.<BR>
By:<U>/s/ Sheppard H.C. Davis, Jr.<BR>
</U>Title:  Authorized Representative</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>SEQUILS - CENTURION V, LTD.<BR>
By:<U>/s/ Steven B. Staver<BR>
</U>Title:  Managing Director</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>SEQUILS - CUMBERLAND I, LTD.<BR>
By:<U>/s/ Dale Burrow<BR>
</U>Title:  Senior Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>SEQUILS-ING I (HBDGM), LTD.<BR>
By:<U>/s/ Helen Rhee<BR>
</U>Title:  Senior Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>SEQUILS-LIBERTY, LTD.<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>SEQUILS-MAGNUM, LTD. (#1280)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>SMOKY RIVER CDO, L.P.<BR>
By:<U>/s/ Melissa Marano<BR>
</U>Title:  Director</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>SUMITOMO TRUST &amp; BANKING CO., LTD.<BR>
By:<U>/s/ Elizabeth A. Quirk<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>SUNAMERICA LIFE INSURANCE COMPANY<BR>
By:<U>/s/ Steven S. Oh<BR>
</U>Title:  Authorized Agent</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>THE TRAVELERS INSURANCE<BR>
By:<U>/s/ Matthew J. McInerny<BR>
</U>Title:  Investment Officer</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>TRITON CBO III, LIMITED<BR>
By:<U>/s/ Thomas H.B. Ewald<BR>
</U>Title:  Authorized Signatory</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>US HIGH YIELD BOND FUND I (#1402)<BR>
By:<U>/s/ Mohan V. Phansalker<BR>
</U>Title:  Executive Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>VAN KAMPEN CLO I, LIMITED<BR>
By:<U>/s/ Brad Langs<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>VAN KAMPEN CLO II, LIMITED<BR>
By:<U>/s/ Brad Langs<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>VAN KAMPEN PRIME RATE INCOME TRUST<BR>
By:<U>/s/ Brad Langs<BR>
</U>Title:  Vice President</P>
</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P>VAN KAMPEN SENIOR FLOATING RATE FUND<BR>
By:<U>/s/ Brad Langs<BR>
</U>Title:  Vice President</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P>VAN KAMPEN SENIOR INCOME TRUST<BR>
By:<U>/s/ Brad Langs<BR>
</U>Title:  Vice President</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<FONT SIZE=3>
<B><P ALIGN="CENTER">CONSENT</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

</B><P>Dated as of December 16, 2002</P>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P>Each of the undersigned, as Guarantors under, as applicable, the (i) Parent Guaranty dated as of October 5, 2001, (ii) Subsidiary Guaranty dated as of October 5, 2001 or (iii) Subsidiary Guaranty dated as of December 26, 2001, in each case in favor of the Secured Parties referred to therein (collectively, the "<B><I>Guaranty</B></I>"), hereby consents to the foregoing Amendment and hereby confirms and agrees that (a)&nbsp;notwithstanding the effectiveness of such Amendment, the Guaranty  is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects, except that, on and after the effectiveness of such Amendment, each reference in the Guaranty to the "Credit Agreement", "thereunder", "thereof" or words of like import shall mean and be a reference to the Credit Agreement, as amended by such Amendment, and (b)&nbsp;each of the Collateral Documents to which such Guarantor is a party and all of the Collateral described therein do, and shall continue to, secure the payment of all of the Secured Obligations (in each case, as defined therein).</P>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>ALPHARMA OPERATING CORPORATION</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA USPD INC. </P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA U.S. INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>BARRE PARENT CORPORATION</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>G.F. REILLY COMPANY</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>PARMED PHARMACEUTICALS, INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA EURO HOLDINGS INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA (BERMUDA) INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA USHP INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA US PHARMACEUTICAL LLC</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA ANIMAL HEALTH COMPANY</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>MIKJAN CORPORATION</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>ALPHARMA NW INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>NMC LABORATORIES, INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>US ORAL PHARMACEUTICALS PTY LTD</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>FAULDING HOLDINGS INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>FAULDING PHARMACEUTICALS INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ John W. LaRocca&#9;</U><BR>
Title:  Assistant Secretary</P>

<P>&nbsp;</P>
<P>POINT HOLDINGS INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ John W. LaRocca&#9;</U><BR>
Title:  Assistant Secretary</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>PUREPAC PHARMACEUTICAL HOLDINGS INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ Robert F. Wrobel&#9;</U><BR>
Title:  Secretary</P>

<P>&nbsp;</P>
<P>FAULDING LABORATORIES INC.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ John W. LaRocca&#9;</U><BR>
Title:  Assistant Secretary</P>

<P>&nbsp;</P>
<P>PUREPAC PHARMACEUTICAL CO.</P>

<P>&nbsp;</P>
<P>By:<U>/s/ John W. LaRocca&#9;</U><BR>
Title:  Assistant Secretary</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</FONT></BODY>
</HTML>

</TEXT>
</DOCUMENT>
